End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
180,900 KRW | +0.72% | -3.26% | -10.22% |
May. 24 | Celltrion Receives European Commission Approval of Omlyclo® (CT-P39), the First and Only Omalizumab Biosimilar Approved in Europe | CI |
May. 10 | Celltrion's Q1 Attributable Profit Slumps 86% | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.22% | 27.17B | |
+51.27% | 63.85B | |
-2.21% | 41.83B | |
+40.01% | 40.47B | |
+13.40% | 26.52B | |
-21.50% | 18.69B | |
+2.83% | 12.73B | |
+21.68% | 12.11B | |
+27.91% | 12.07B | |
-9.83% | 11.19B |
- Stock Market
- Equities
- A068270 Stock
- News Celltrion, Inc.
- South Korean Shares Dip on Tech, Pharma Losses; Celltrion Sheds 5% on Lackluster Q4 Earnings